Shain KH - Search Results

1

Sequence of novel agents in multiple myeloma: an instrumental variable analysis.

Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Baz R, et al. Among authors: shain kh. Leuk Res. 2013 Sep;37(9):1077-82. doi: 10.1016/j.leukres.2013.06.005. Epub 2013 Jun 25. Leuk Res. 2013. PMID: 23809054

2

Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation.

Landowski TH, Shain KH, Oshiro MM, Buyuksal I, Painter JS, Dalton WS. Landowski TH, et al. Among authors: shain kh. Blood. 1999 Jul 1;94(1):265-74. Blood. 1999. PMID: 10381522 Free article.

3

Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line.

Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Shain KH, et al. Leukemia. 2000 May;14(5):830-40. doi: 10.1038/sj.leu.2401776. Leukemia. 2000. PMID: 10803514

4

The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance.

Shain KH, Landowski TH, Dalton WS. Shain KH, et al. Curr Opin Oncol. 2000 Nov;12(6):557-63. doi: 10.1097/00001622-200011000-00008. Curr Opin Oncol. 2000. PMID: 11085455 Review.

5

Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest.

Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H. Niu G, et al. Among authors: shain kh. Cancer Res. 2001 Apr 15;61(8):3276-80. Cancer Res. 2001. PMID: 11309279

6

Multiple Myeloma: New Insights and Therapeutic Approaches.

Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Anderson KC, et al. Hematology Am Soc Hematol Educ Program. 2000:147-165. doi: 10.1182/asheducation-2000.1.147. Hematology Am Soc Hematol Educ Program. 2000. PMID: 11701540

7

Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines.

Shain KH, Landowski TH, Dalton WS. Shain KH, et al. J Immunol. 2002 Mar 1;168(5):2544-53. doi: 10.4049/jimmunol.168.5.2544. J Immunol. 2002. PMID: 11859150

8

Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR.

Shain KH, Dalton WS. Shain KH, et al. Mol Cancer Ther. 2001 Nov;1(1):69-78. Mol Cancer Ther. 2001. PMID: 12467240 Review.

9

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS. Hazlehurst LA, et al. Among authors: shain kh. Cancer Res. 2003 Nov 15;63(22):7900-6. Cancer Res. 2003. PMID: 14633719

10

Targeting the bone marrow microenvironment in hematologic malignancies.

Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M. Dalton WS, et al. Semin Hematol. 2004 Apr;41(2 Suppl 4):1-5. doi: 10.1053/j.seminhematol.2004.02.001. Semin Hematol. 2004. PMID: 15190509 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters